TR201908199T4 - HPV'ye karşı aşılar. - Google Patents

HPV'ye karşı aşılar. Download PDF

Info

Publication number
TR201908199T4
TR201908199T4 TR2019/08199T TR201908199T TR201908199T4 TR 201908199 T4 TR201908199 T4 TR 201908199T4 TR 2019/08199 T TR2019/08199 T TR 2019/08199T TR 201908199 T TR201908199 T TR 201908199T TR 201908199 T4 TR201908199 T4 TR 201908199T4
Authority
TR
Turkey
Prior art keywords
vaccines against
hpv
methods
peptides
relates
Prior art date
Application number
TR2019/08199T
Other languages
English (en)
Inventor
Henrik Brekke Ole
Brunsvik Fredriksen Agnete
AREFFARD Ali
Mari Lindeberg Mona
Original Assignee
Vaccibody As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccibody As filed Critical Vaccibody As
Publication of TR201908199T4 publication Critical patent/TR201908199T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Mevcut buluş, insan papillom virüsüne (HPV) karşı aşılar, özellikle HPV16 veya HPV18'e karşı DNA aşıları gibi terapötik bileşikler ile ilgilidir. Buluş ayrıca, homodimerik peptitleri kodlayan protein yapısı ile ilgilidir ve söz konusu peptitler, bir DNA aşısından salınır veya ayrı ayrı kullanılır. Ayrıca farmasötik formülasyonlar, konak hücreler ve aşıların üretilmesine yönelik yöntemler ve aynı zamanda kanser ve bulaşıcı hastalıklar gibi çeşitli HPV kaynaklı hastalıkların, uygulama yoluyla tedavi edilmesine yönelik yöntemler tarif edilmiştir.
TR2019/08199T 2011-12-21 2012-12-20 HPV'ye karşı aşılar. TR201908199T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161578542P 2011-12-21 2011-12-21

Publications (1)

Publication Number Publication Date
TR201908199T4 true TR201908199T4 (tr) 2019-06-21

Family

ID=47471832

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08199T TR201908199T4 (tr) 2011-12-21 2012-12-20 HPV'ye karşı aşılar.

Country Status (18)

Country Link
US (1) US9901635B2 (tr)
EP (2) EP2793937B1 (tr)
JP (1) JP6258864B2 (tr)
KR (1) KR102057265B1 (tr)
CN (1) CN104039833B (tr)
AU (1) AU2012356969B2 (tr)
BR (1) BR112014015016B1 (tr)
CA (1) CA2858963C (tr)
DK (1) DK2793937T3 (tr)
ES (1) ES2730718T3 (tr)
HK (1) HK1202442A1 (tr)
HU (1) HUE043361T2 (tr)
IL (1) IL233217B (tr)
PT (1) PT2793937T (tr)
RU (1) RU2644201C2 (tr)
TR (1) TR201908199T4 (tr)
WO (1) WO2013092875A1 (tr)
ZA (1) ZA201404516B (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140176A1 (en) * 2013-03-15 2014-09-18 Vaccibody As Targeting vaccines for veterinary use
EP3094652B1 (en) * 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CN107073070A (zh) 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
SG10202001501QA (en) * 2015-08-20 2020-04-29 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines
WO2019048928A1 (en) * 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
US20210069319A1 (en) * 2017-09-07 2021-03-11 University Of Oslo Vaccine molecules
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
KR20240029786A (ko) 2020-04-24 2024-03-06 주식회사 제넥신 자궁경부암 치료방법
WO2021219897A1 (en) 2020-05-01 2021-11-04 Vaccibody As Betacoronavirus prophylaxis and therapy
BR112023019610A2 (pt) 2021-03-26 2023-12-12 Genentech Inc Método para tratar um sujeito com câncer, e, kit
EP4333881A1 (en) 2021-05-03 2024-03-13 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
EP4337251A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and composition and their use for the treatment of immune disorders
BR112023023260A2 (pt) 2021-05-10 2024-01-30 Nykode Therapeutics ASA Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
IL308312A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Expression from a combination of inhibitory structures and compounds
WO2022238395A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
AU2022381515A1 (en) 2021-11-03 2024-05-09 Adaptive Biotechnologies Corporation Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
CN1720060B (zh) * 2002-10-03 2011-12-14 惠氏控股公司 人乳头瘤病毒多肽和免疫原性组合物
US8932603B2 (en) * 2003-02-25 2015-01-13 Vaccibody As Modified antibody
EP1576967B1 (en) * 2004-03-18 2007-09-12 Institut Pasteur Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof
JP2008528004A (ja) 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン
EP2585107B1 (en) * 2010-06-25 2018-10-24 Vaccibody AS Homodimeric protein constructs

Also Published As

Publication number Publication date
US20150056197A1 (en) 2015-02-26
KR102057265B1 (ko) 2019-12-18
EP2793937A1 (en) 2014-10-29
JP2015508284A (ja) 2015-03-19
PT2793937T (pt) 2019-06-05
US9901635B2 (en) 2018-02-27
RU2014129788A (ru) 2016-02-10
ZA201404516B (en) 2017-04-26
BR112014015016B1 (pt) 2023-10-03
IL233217B (en) 2019-05-30
US20150306217A9 (en) 2015-10-29
CA2858963A1 (en) 2013-06-27
AU2012356969B2 (en) 2017-05-04
BR112014015016A2 (pt) 2020-10-27
EP2793937B1 (en) 2019-04-10
CN104039833A (zh) 2014-09-10
HK1202442A1 (en) 2015-10-02
BR112014015016A8 (pt) 2023-05-09
WO2013092875A1 (en) 2013-06-27
DK2793937T3 (da) 2019-07-01
CA2858963C (en) 2023-05-23
EP3533462A1 (en) 2019-09-04
AU2012356969A1 (en) 2014-07-03
HUE043361T2 (hu) 2019-08-28
CN104039833B (zh) 2018-01-30
RU2644201C2 (ru) 2018-02-08
JP6258864B2 (ja) 2018-01-10
IL233217A0 (en) 2014-08-31
NZ626124A (en) 2016-07-29
ES2730718T3 (es) 2019-11-12
KR20140107569A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
TR201908199T4 (tr) HPV'ye karşı aşılar.
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
PH12015500931A1 (en) Recombinant particle based vaccines against human cytomegalovirus infection
BR112013030150A2 (pt) proteína l1 hpv33 truncada ou variante da mesma, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv33, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv33 truncada, método para preparar a partícula do tipo viral hpv33, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada pela infecção de hpv e uso da proteína l1 hpv33 truncada ou variante da mesma
EA201591688A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
EA201170965A1 (ru) Усовершенствованные вакцины вируса человеческой папилломы и способы их использования
EA201390806A1 (ru) Конструкция пептидного каркаса
RU2019107976A (ru) Композиция вакцины
EP2568289A3 (en) Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
IN2015DN02546A (tr)
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
JP2015533376A5 (tr)
EP2589604A4 (en) SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
JP2015504897A5 (tr)
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
JP2010506926A5 (tr)
WO2015095167A3 (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
EA201490220A1 (ru) Композиция и способ лечения hpv
WO2013006401A3 (en) Methods and compositions of protein antigens for the diagnosis and treatment of herpes simplex viruses type 1 and 2